AAPGV - רווח תפעולי לפני ניכוי פחת Ascentage Pharma Group International

Ascentage Pharma Group is automating the search for oncoprotein inhibitors through robotic molecular design, eliminating manual labor. The cash EBITDA trend reflects the current financial result of operations, where the indicator value stands at 0.00. The company is minimizing lab technician involvement in tests by implementing software robots to process targeted therapy data sets and perform molecular screening.

The investment attractiveness of Ascentage Pharma Group (AAPGV) is based on the international management's ability to monetize oncology developments in the Chinese and US markets. An analysis of absolute EBITDA allows for an assessment of the real efficiency of the operating cycle, excluding debt load and asset depreciation, confirming the business's financial stability amid the Fed's tight monetary policy.